

## Anti-TNFRSF18/GITR/CD357 Antibody (Korea Natl.Cancer Ctr. patent anti-GITR)

### Introduction

Korea Natl.Cancer Ctr. patent anti-GITR is a CHO-expressed humanized antibody targeting TNFRSF18 / GITR / CD357.

### Product parameters

Alternative Names	Korea Natl.Cancer Ctr. patent anti-GITR
Target Accession	Q9Y5U5
Target	TNFRSF18 / GITR / CD357
CAS number	/
Molecular Weight	150 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

